MDR1, MRP1 and LRP expression in patients with untreated acute leukaemia: Correlation with 99mTc-MIBI bone marrow scintigraphy

Nuclear Medicine Communications

Volumn 28, Issue 7, 2007, Pages 541-546

  Ak, Ýlknur ^a   Demirel, Gülcihan ^a   Gülbas, Zafer ^a  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Leukaemia; LRP

Indexed keywords

LUNG RESISTANCE PROTEIN; MESSENGER RNA; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN 1;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW SCINTISCANNING; CANCER PATIENT; CLINICAL ARTICLE; CORRELATION COEFFICIENT; FEMALE; GENE OVEREXPRESSION; HUMAN; MALE; MEDICAL ASSESSMENT; MESSENGER RNA SYNTHESIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; ORGANOTECHNETIUM COMPOUNDS; P-GLYCOPROTEIN; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN; STATISTICS; TUMOR MARKERS, BIOLOGICAL; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 34249828958     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328194f1cd     Document Type: Article

References (41)

1. Buchner T. Treatment of adult acute leukemia. Curr Opin Oncol 1997; 9:18-25.
2. Bradshaw D, Arceci R. Clinical relevance of transmembrane drug efflux as a multidrug resistance. J Clin Oncol 1998; 16:3674-3690.
3. Teodori E, Dei S, Scapecchi S, Gualtieri F. The medicinal chemistry of multidrug resistance (MDR) reversing drugs. Farmaco 2002; 57:385-415.
4. Masanek U, Stammler G, Volm M. Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides. J Exp Ther Oncol 2002; 2:37-41.
5. Trock B, Leonessa J, Clarke R. Multidrug resistance in breast cancer: a meta analyses of MDR1/Pgp 170 expression and its possible functional significance. J Natl Cancer Inst 1997; 89:917-931.
6. Poeta G, Stasi R, Aronica G, Venditti A, Cox M, Bruno A, et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 1996; 87:1997-2004.
7. Wackers F, Berman D, Maddahi J, Watson D, Beller G, Strauss H, et al. Technetium-99m hexakis 2-methoxyisobutylisonitrile: human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989; 30:301-311.
8. Chiu M, Kronauge J, Piwnika-Worms D. Effect of mitocondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile)-technetium(I) in cultured mouse fibroblast. J Nucl Med 1990; 31:1646-1653.
9. Delmon-Moingeon L, Piwnica-Worms D, Van den Abbeele A, Holman L, Davidson A, Jones A. Uptake of cation hexakis (2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell line in vitro. Cancer Res 1990; 50:2198-2202.
10. Piwnica-Worms D, Kronauge J, Chiu M. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990; 82:1826-1838.
11. 99mTc-MIBI uptake and angiogenesis in MIBI-positive breast lesions. Nucl Med Biol 2005; 32:465-472.
12. Ak I, Gulbas Z. Nuclear medicine applications in hemato-oncology. Turk J Haematol 2003; 20:189-211.
13. 99mTc-MIBI whole body scintigraphy in active and in remission multiple myeloma. Hell J Nucl Med 2005; 8:165-168.
14. Ak I, Aslan V, Vardareli E, Gulbas Z. Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells. Ann Hematol 2003; 82:88-92.
15. Nandurkar D, Kalff V, Turlakow A, Spencer A, Bailey M, Kelly M. Focal MIBI uptake is a better indicator of active myeloma than diffuse uptake. Eur J Haematol 2006; 76:141-146.
16. 99mTc-MIBI bone marrow imaging in patients with untreated leukaemia. Nucl Med Commun 2003; 24:397-402.
17. Kostakoglu L, Guc D, Canpinar H, Kars A, Alper E, Kiratli P, et al. P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy. J Nucl Med 1998; 39:1191-1197.
18. Gruber A, Arestrom I, Xu D, Liliemark J, Larsson S, Jacobsson H. Multidrug resistance phenotype in leukaemic cells from patients with acute myelocytic leukaemia can be detected with 99Tc(m)-MIBI. Br J Cancer 1998; 77:1732-1736.
19. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer 1998; 77:353-358.
20. Kao A, Shiun S, Hsu N, Sun S, Lee C, Lin C. Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression. Ann Oncol 2001; 12:1561-1566.
21. Larsen A, Escargueil A, Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 2000; 85:217-229.
22. Pfaffl W. A new mathematical model for relative quantification in real-time RT-PCR. Nucl Acids Res 2001; 29:45.
23. Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med 2000; 247:521-534.
24. van den Heuvel-Eibrink M, Sonneveld P, Pieters R. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharm Ther 2000; 38:94-110.
25. Muller M, Meijer C, Zaman G, Borst P, Scheper R, Mulder H, et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATPdependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 1994; 91:13033-13037.
26. Scheffer G, Wijngaard P, Flens M, Izquierdo M, Slovak M, Pinedo H, et al. The drug resistance-related protein LRP is the human major vault protein. Nat Med 1995; 1:578-582.
27. Scheffer G, Schroeijers A, Izquierdo M, Wiemer E, Scheper R. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 2000; 12:550-556.
28. Pall G, Spitaler M, Hofmann J, Thaler J, Ludescher CP. Multidrug resistance in acute leukemia: a comparison of different diagnostic methods. Leukemia 1997; 11:1067-1072.
29. Kobayashi H, Takemura Y, Kawai Y, Miyachi H, Kawabata M, Matsumura T, et al. Competitive reverse transcription-polymerase chain reaction assay for quantification of human multidrug resistance 1 (MDR1) gene expression in fresh leukaemic cells. J Lab Clin Med 2000; 135:199-209.
30. Fujimaki S, Funato T, Harigae H, Fujiwara J, Kameoka J, Meguro K, et al. Quantitative analysis of a MDR1 transcript for prediction of drug resistance in acute leukemia. Clin Chem 2002; 48:811-817.
31. 99mTc-MIBI imaging in patients with lung cancer. J Nucl Med 2001; 42:1476-1483.
32. Tothova E, Elbertova A, Fricova M, Kafkova A, Hlebaskova M, Svorcova E, et al. P-glycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome. Neoplasma 2001; 48:393-397.
33. Wuchter C, Leonid K, Ruppert V, Schrappe M, Buchner T, Schoch C, et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000; 85:711-721.
34. Swerts K, de Moerloose B, Dhooge C, Noens L, Laureys G, Benoit Y, Philippe J. Comparison of two functional flow cytometric assays to assess P-gp activity in acute leukemia. Leuk Lymphoma 2004; 45:2221-2228.
35. Chauncey TR. Chemotherapy resistance in acute leukemia. Turk J Haematol 2000; 17:155-162.
36. Brophy NA, Marie JP, Rojas VA, Warnke RA, McFall PJ, Smith SD, et al. Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical evaluation by four techniques. Leukemia 1994; 8:327-335.
37. Ivy SP, Olshefski RS, Taylor BJ, Patel KM, Reaman GH. Correlation of P-lycoprotein expression and function in childhood acute leukemia: a children's cancer group study. Blood 1996; 88:309-318.
38. Goasguen JE, Dossot JM, Fardel O, Le Mee F, Le Gall E, Leblay R, et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993; 81:2394-2398.
39. Sauerbrey A, Voigt A, Wittig S, Hafer R, Zintl F. Messenger RNA analysis of the multidrug resistance related protein (MRP1) and the lung resistance protein (LRP) in de novo and relapsed childhood acute lymphoblastic leukemia. Leuk Lymphoma 2002; 43:875-879.
40. Huh H, Park C, Jang S, Seo E, Chi H, Lee J, et al. Prognostic significance of multidrug resistance gene 1 (MDR1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) mRNA expression in acute leukemia. J Korean Med Sci 2006; 21:253-258.
41. Valera E, Scrideli C, Queiroz R, Mori B, Tone L. Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia. Sao Paulo Med J 2004; 122:166-171.